Physician profile
Srinivas Koya
NPI 1376650010
$5,164.32
in general payments reported to CMS, 2019-2025
28 companies · $565 in 2025
The $565 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $595 · 2021: $989 · 2022: $898 · 2023: $739 · 2024: $773 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.51 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $665.79 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $635.31 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $621.20 | 2019-2024 | Xarelto |
| Pfizer INC. | $535.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $530.70 | 2019-2024 | Fasenra, Farxiga |
| Abbvie INC. | $412.72 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $267.83 | 2019-2024 | Dificid, Verquvo, Zerbaxa |
| Electromed, INC. | $232.28 | 2019-2024 | Smartvest |
| Paratek Pharmaceuticals, INC. | $161.12 | 2020-2022 | |
| Gilead Sciences, INC. | $155.36 | 2021-2023 | Veklury |
| Novo Nordisk INC | $137.89 | 2024-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.26 | 2020-2025 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.94 | 2022-2025 | Lifevest |
| Otsuka America Pharmaceutical, INC. | $113.18 | 2019 | |
| Allergan, INC. | $96.17 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $87.32 | 2021-2023 | Ultomiris |
| Nabriva Therapeutics, Plc | $41.40 | 2021 | |
| Sunovion Pharmaceuticals INC. | $27.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.86 | 2024 | Eliquis |
| Abbott Laboratories | $23.92 | 2022 | |
| Medtronic, INC. | $22.97 | 2021 | |
| Portola Pharmaceuticals, LLC | $22.32 | 2019 | |
| Insmed, INC. | $21.78 | 2023 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $20.04 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.01 | 2023 | Givlaari |
| Kci USA, INC. | $18.96 | 2019 | |
| Amgen INC. | $15.78 | 2019 | |
| Melinta Therapeutics, LLC | $15.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Koya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.